Conclusions:
"Based on un-adjudicated reports, there
appears to be a 3.2-fold risk of lung cancer and 2.3-fold
risk of lung cancer mortality among patients randomized
to Exubera. There was no evidence of increased risk of all
cause mortality."
This doesn't sound great for Pfizer,but it's not going to help Afrezza's case either even if it is apples to oranges.
Thanks for sharing,MN.